<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40980163</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5559</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JHEP reports : innovation in hepatology</Title><ISOAbbreviation>JHEP Rep</ISOAbbreviation></Journal><ArticleTitle>Proteomic signatures reflect effects of semaglutide treatment for MASH.</ArticleTitle><Pagination><StartPage>101521</StartPage><MedlinePgn>101521</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101521</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhepr.2025.101521</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="UNASSIGNED">Proteomic technology has emerged as a non-invasive method for grading and staging metabolic dysfunction-associated steatohepatitis (MASH). The aims of this <i>post hoc</i> analysis of the STEP 1 and STEP 2 trials were to assess the distribution of SomaSignal-derived MASH components, evaluate the effect of semaglutide (2.4 mg and 1.0 mg) on these components, and test concordance with biopsy-based MASH histology from the phase IIb Sema-MASH trial.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Participants with overweight or obesity (STEP 1) and type 2 diabetes (STEP 2), who received once-weekly semaglutide or placebo for 68 weeks and had available biological samples, were included. In addition, participants with biopsy-confirmed MASH from the phase IIb Sema-MASH trial who received once-daily semaglutide or placebo for 72 weeks were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">SomaSignal-derived steatosis was prevalent in both STEP 1 (43.2%) and STEP 2 (71.7%). At week 68, participants who received semaglutide had significantly lower odds of exhibiting SomaSignal-defined MASH components compared with those on placebo. They were also more likely to have a less severe SomaSignal-derived stage of metabolic dysfunction-associated steatotic liver disease, with odds ratios for semaglutide 2.4 mg of 5.26 (95% CI 3.59-7.72) in STEP 1 and 4.90 (95% CI 2.86-8.40) in STEP 2; both <i>p</i> &lt;0.0001. SomaSignal-derived MASH components correlated with histologic changes, standard liver-related biomarkers, and measures of glycemic control.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">These findings suggest that SomaSignal MASH component testing may be useful for evaluating the potential therapeutic effects of semaglutide in patients with MASH and related comorbidities. However, prospective randomized clinical trials are necessary to confirm these results.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION NUMBERS" NlmCategory="UNASSIGNED">STEP 1: NCT03548935; STEP 2: NCT03552757; MASH phase IIb trial: NCT02970942.</AbstractText><AbstractText Label="IMPACT AND IMPLICATIONS" NlmCategory="UNASSIGNED">Liver biopsy is the current gold standard for the diagnosis of metabolic dysfunction-associated steatohepatitis (MASH); however, this procedure is invasive and time consuming for patients living with MASH. The use of non-invasive tests to diagnose MASH is becoming increasingly popular and many clinicians see this approach as the diagnostic future. SomaSignal is a proteomics-based model designed to non-invasively test for and validate MASH components as well as detect the prevalence of metabolic dysfunction-associated steatotic liver disease stages, against biopsy results. In the future, SomaSignal MASH components may have an impact on future clinical practice by providing clinicians with an alternative option for non-invasive assessment of treatment effects in the early clinical stages of therapeutic development.</AbstractText><CopyrightInformation>&#xa9; 2025 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schattenberg</LastName><ForeName>J&#xf6;rn M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, Saarland University Medical Center, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xf8;nb&#xe6;k</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatology &amp; Gastroenterology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kliers</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, S&#xf8;borg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladelund</LastName><ForeName>Steen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, S&#xf8;borg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Michelle T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, S&#xf8;borg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyg&#xe5;rd</LastName><ForeName>Sune Boris</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, S&#xf8;borg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanyal</LastName><ForeName>Arun J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, School of Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Melanie J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Diabetes Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Leicester Biomedical Research Centre, Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03548935</AccessionNumber><AccessionNumber>NCT02970942</AccessionNumber><AccessionNumber>NCT03552757</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JHEP Rep</MedlineTA><NlmUniqueID>101761237</NlmUniqueID><ISSNLinking>2589-5559</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ballooning</Keyword><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Metabolic Dysfunction-Associated Steatohepatitis</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword><Keyword MajorTopicYN="N">Type 2 Diabetes</Keyword></KeywordList><CoiStatement>JMS declares consultant honoraria from 89bio, Alentis, Alexion, Altimmune, AstraZeneca, Bionorica, Boehringer Ingelheim, Gilead Sciences, GSK, Inventiva Pharma, Ipsen, Lilly, Madrigal Pharmaceuticals, MSD, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Siemens Healthineers; speaker honoraria from AbbVie, Academic Medical Education (AME), Boehringer Ingelheim, Echosens, Forum f&#xfc;r Medizinische Fortbildung (FOMF), Gilead Sciences, Madrigal Pharmaceuticals MedicalTribune, MedPublico GmbH, MedScape, and Novo Nordisk; and stockholder options in AGED Diagnostics and Hepta Bio. HG declares research grants from AbbVie, ADS AIPHIA Development Services AG Intercept, ARLA Food for Health, and Intercept; declares consulting fees from Ipsen, NOVO, and Pfizer; is a lecturer for AstraZeneca and Eisai; and is on the Data Monitoring Committee of CAMURUS AB. IK, SL, MTL, and SBN are employees and stakeholders of Novo Nordisk A/S. AJS has stockholder options in Durect, Exhalenz, Genfit, Inversago, Rivus, and Tiziana; has served as a consultant to 89bio, Akero, Aligos, Alnylam, Altimmune, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, Hanmi, Histoindex, Intercept, Madrigal Pharmaceuticals, Merck, Myovant, Northsea, Novo Nordisk, Path AI, Pfizer, Poxel, Promed, Regeneron, Salix, Surrozen, Takeda, and Zydus; his institution has received grants from Boehringer Ingelheim, Echosens, Eli Lilly, Gilead, Hanmi, Intercept, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Salix, and Takeda; and he receives royalties from Elsevier and Wolter Kluwers. MJD has acted as consultant, advisory board member, and speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; an advisory board member and speaker for AstraZeneca; an advisory board member for Carmot, Pfizer, Roche, ShouTi Pharma, and Zealand; and a speaker for Amgen and Sanofi. MJD has received grants as an investigator in support of investigator-initiated trials from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, and Sanofi-Aventis. Please refer to the accompanying ICMJE disclosure forms for further details.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>8</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40980163</ArticleId><ArticleId IdType="pmc">PMC12447996</ArticleId><ArticleId IdType="doi">10.1016/j.jhepr.2025.101521</ArticleId><ArticleId IdType="pii">S2589-5559(25)00200-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rinella M.E., Lazarus J.V., Ratziu V., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966&#x2013;1986. doi: 10.1097/HEP.0000000000000520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HEP.0000000000000520</ArticleId><ArticleId IdType="pmc">PMC10653297</ArticleId><ArticleId IdType="pubmed">37363821</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta U., Ruli T., Buttar D., et al. Metabolic dysfunction associated steatotic liver disease: current practice, screening guidelines and management in the primary care setting. Am J Med Sci. 2024;367(2):77&#x2013;88. doi: 10.1016/j.amjms.2023.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2023.11.007</ArticleId><ArticleId IdType="pubmed">37967750</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao L., Targher G., Byrne C.D., et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35(8):697&#x2013;707. doi: 10.1016/j.tem.2024.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2024.02.007</ArticleId><ArticleId IdType="pubmed">38429161</ArticleId></ArticleIdList></Reference><Reference><Citation>Schattenberg J.M., Lazarus J.V., Newsome P.N., et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int. 2021;41(6):1227&#x2013;1242. doi: 10.1111/liv.14825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14825</ArticleId><ArticleId IdType="pmc">PMC8252761</ArticleId><ArticleId IdType="pubmed">33590598</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X.D., Targher G., Byrne C.D., et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773&#x2013;791. doi: 10.1007/s12072-023-10543-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-023-10543-8</ArticleId><ArticleId IdType="pmc">PMC10198034</ArticleId><ArticleId IdType="pubmed">37204656</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong M.J. Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: from bench to bedside. Clin Liver Dis (Hoboken) 2017;10(2):32&#x2013;35. doi: 10.1002/cld.650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cld.650</ArticleId><ArticleId IdType="pmc">PMC6467104</ArticleId><ArticleId IdType="pubmed">30992756</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber Y., Boyle M., Hallsworth K., et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol. 2019;17(10):2085&#x2013;2092.e2081. doi: 10.1016/j.cgh.2018.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2018.12.016</ArticleId><ArticleId IdType="pubmed">30580090</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Hara J., Finnegan A., Dhillon H., et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep. 2020;2(5) doi: 10.1016/j.jhepr.2020.100142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhepr.2020.100142</ArticleId><ArticleId IdType="pmc">PMC7397699</ArticleId><ArticleId IdType="pubmed">32775976</ArticleId></ArticleIdList></Reference><Reference><Citation>Schattenberg J.M., Straub B.K. On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis. J Hepatol. 2020;73(6):1592&#x2013;1593. doi: 10.1016/j.jhep.2020.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.07.020</ArticleId><ArticleId IdType="pubmed">32933780</ArticleId></ArticleIdList></Reference><Reference><Citation>Arun J., Jhala N., Lazenby A.J., et al. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes Surg. 2007;17(2):155&#x2013;161. doi: 10.1007/s11695-007-9041-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11695-007-9041-2</ArticleId><ArticleId IdType="pubmed">17476865</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu K.W., Thorn R.G., Vatsia S.K., et al. Unusual presentation of metastatic carcinoma of prostate. Urol Int. 1986;41(3):228&#x2013;231. doi: 10.1159/000281205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000281205</ArticleId><ArticleId IdType="pubmed">3750590</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison S.A., Bedossa P., Guy C.D., et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497&#x2013;509. doi: 10.1056/NEJMoa2309000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2309000</ArticleId><ArticleId IdType="pubmed">38324483</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Accessed June 6, 2025.</Citation></Reference><Reference><Citation>Loomba R., Hartman M.L., Lawitz E.J., et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299&#x2013;310. doi: 10.1056/NEJMoa2401943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2401943</ArticleId><ArticleId IdType="pubmed">38856224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal A.J., Bedossa P., Fraessdorf M., et al. A phase II randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311&#x2013;319. doi: 10.1056/NEJMoa2401755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2401755</ArticleId><ArticleId IdType="pubmed">38847460</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration  . 2020. Highlights of Prescribing Information. OZEMPIC (semaglutide) injection, for subcutaneous use.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  . 2019. Highlights of Prescribing Information. RYBELSUS (semaglutide) tablets, for oral use.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  . 2021. Highlights of Prescribing Information. WEGOVY (semaglutide) injection, for subcutaneous use.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf</Citation></Reference><Reference><Citation>Newsome P.N., Buchholtz K., Cusi K., et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113&#x2013;1124. doi: 10.1056/NEJMoa2028395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028395</ArticleId><ArticleId IdType="pubmed">33185364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal A.J., Newsome P.N., Kliers I., et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089&#x2013;2099. doi: 10.1056/NEJMoa2413258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2413258</ArticleId><ArticleId IdType="pubmed">40305708</ArticleId></ArticleIdList></Reference><Reference><Citation>Somalogic. SomaSignal tests. https://somalogic.com/somasignal-tests-for-research-use/. Accessed June 6, 2025.</Citation></Reference><Reference><Citation>Sanyal A.J., Williams S.A., Lavine J.E., et al. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2023;78(4):693&#x2013;703. doi: 10.1016/j.jhep.2022.11.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2022.11.029</ArticleId><ArticleId IdType="pmc">PMC10165617</ArticleId><ArticleId IdType="pubmed">36528237</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Wadhawan S., Greenfield A., et al. SOMAscan proteomics identifies serum biomarkers associated with liver fibrosis in patients with NASH. Hepatol Commun. 2021;5(5):760&#x2013;773. doi: 10.1002/hep4.1670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep4.1670</ArticleId><ArticleId IdType="pmc">PMC8122380</ArticleId><ArticleId IdType="pubmed">34027267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilding J.P.H., Batterham R.L., Calanna S., et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989&#x2013;1002. doi: 10.1056/NEJMoa2032183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2032183</ArticleId><ArticleId IdType="pubmed">33567185</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies M., F&#xe6;rch L., Jeppesen O.K., et al. Semaglutide 2&#xb7;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971&#x2013;984. doi: 10.1016/s0140-6736(21)00213-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00213-0</ArticleId><ArticleId IdType="pubmed">33667417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313&#x2013;1321. doi: 10.1002/hep.20701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20701</ArticleId><ArticleId IdType="pubmed">15915461</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson S., Hardy T., Dufour J.F., et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740&#x2013;751. doi: 10.1038/ajg.2016.453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.453</ArticleId><ArticleId IdType="pmc">PMC5418560</ArticleId><ArticleId IdType="pubmed">27725647</ArticleId></ArticleIdList></Reference><Reference><Citation>Quek J., Chan K.E., Wong Z.Y., et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20&#x2013;30. doi: 10.1016/S2468-1253(22)00317-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(22)00317-X</ArticleId><ArticleId IdType="pubmed">36400097</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi Z.M., Golabi P., de Avila L., et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793&#x2013;801. doi: 10.1016/j.jhep.2019.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2019.06.021</ArticleId><ArticleId IdType="pubmed">31279902</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark J.M., Cryer D.R.H., Morton M., et al. Nonalcoholic fatty liver disease from a primary care perspective. Diabetes Obes Metab. 2023;25(6):1421&#x2013;1433. doi: 10.1111/dom.15016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15016</ArticleId><ArticleId IdType="pubmed">36789676</ArticleId></ArticleIdList></Reference><Reference><Citation>Labenz C., Huber Y., Kalliga E., et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther. 2018;48(10):1109&#x2013;1116. doi: 10.1111/apt.14976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.14976</ArticleId><ArticleId IdType="pubmed">30288767</ArticleId></ArticleIdList></Reference><Reference><Citation>Noureddin M., Yates K.P., Vaughn I.A., et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58(5):1644&#x2013;1654. doi: 10.1002/hep.26465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26465</ArticleId><ArticleId IdType="pmc">PMC3760979</ArticleId><ArticleId IdType="pubmed">23686698</ArticleId></ArticleIdList></Reference><Reference><Citation>Vali Y., Lee J., Boursier J., et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8(8):714&#x2013;725. doi: 10.1016/S2468-1253(23)00017-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(23)00017-1</ArticleId><ArticleId IdType="pubmed">36958367</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown E.A., Minnich A., Sanyal A.J., et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Rep. 2023;5(4) doi: 10.1016/j.jhepr.2022.100661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhepr.2022.100661</ArticleId><ArticleId IdType="pmc">PMC9971179</ArticleId><ArticleId IdType="pubmed">36866389</ArticleId></ArticleIdList></Reference><Reference><Citation>European Association for the Study of the Liver EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659&#x2013;689. doi: 10.1016/j.jhep.2021.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.05.025</ArticleId><ArticleId IdType="pubmed">34166721</ArticleId></ArticleIdList></Reference><Reference><Citation>European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388&#x2013;1402. doi: 10.1016/j.jhep.2015.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2015.11.004</ArticleId><ArticleId IdType="pubmed">27062661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwal F., Shubrook J.H., Adams L.A., et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657&#x2013;1669. doi: 10.1053/j.gastro.2021.07.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.07.049</ArticleId><ArticleId IdType="pmc">PMC8819923</ArticleId><ArticleId IdType="pubmed">34602251</ArticleId></ArticleIdList></Reference><Reference><Citation>ElSayed N.A., Aleppo G., Aroda V.R., et al. Introduction and methodology: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S1&#x2013;S4. doi: 10.2337/dc23-Sint.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc23-Sint</ArticleId><ArticleId IdType="pmc">PMC9810461</ArticleId><ArticleId IdType="pubmed">36507647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalas M.A., Chavez L., Leon M., et al. Abnormal liver enzymes: a review for clinicians. World J Hepatol. 2021;13(11):1688&#x2013;1698. doi: 10.4254/wjh.v13.i11.1688.</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v13.i11.1688</ArticleId><ArticleId IdType="pmc">PMC8637680</ArticleId><ArticleId IdType="pubmed">34904038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan W.L., Chandra Kumar C.V., Chan W.K. Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitis. Hepatobiliary Surg Nutr. 2023;12(5):763&#x2013;767. doi: 10.21037/hbsn-23-346.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/hbsn-23-346</ArticleId><ArticleId IdType="pmc">PMC10598320</ArticleId><ArticleId IdType="pubmed">37886205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanai H., Adachi H., Hakoshima M., et al. Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. Int J Mol Sci. 2023;24(20) doi: 10.3390/ijms242015473.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242015473</ArticleId><ArticleId IdType="pmc">PMC10607514</ArticleId><ArticleId IdType="pubmed">37895151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchison A.L., Tavaglione F., Romeo S., et al. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance. J Hepatol. 2023;79(6):1524&#x2013;1541. doi: 10.1016/j.jhep.2023.08.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2023.08.030</ArticleId><ArticleId IdType="pubmed">37730124</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>